Biomerica (NASDAQ:BMRA) Posts Quarterly Earnings Results, Beats Estimates By $0.83 EPS

Biomerica (NASDAQ:BMRA) released its earnings results on Thursday. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.83, Zacks reports. Biomerica had a negative return on equity of 97.19% and a negative net margin of 84.79%.

Biomerica Stock Performance

Shares of Biomerica stock traded up $0.04 during trading on Thursday, hitting $1.84. The company’s stock had a trading volume of 13,846 shares, compared to its average volume of 36,222. The company has a fifty day simple moving average of $2.04 and a two-hundred day simple moving average of $2.01. The company has a market capitalization of $5.69 million, a PE ratio of -1.45 and a beta of 0.38. Biomerica has a 52 week low of $1.45 and a 52 week high of $3.21.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Biomerica from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has a consensus rating of “Sell” and an average price target of $9.00.

Insider Activity at Biomerica

In other Biomerica news, Director M. Huff Gary acquired 31,250 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were acquired at an average price of $1.60 per share, with a total value of $50,000.00. Following the completion of the purchase, the director directly owned 51,250 shares of the company’s stock, valued at approximately $82,000. The trade was a 156.25% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Vice Chairman Allen Barbieri acquired 20,000 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was acquired at an average price of $1.60 per share, for a total transaction of $32,000.00. Following the acquisition, the insider owned 73,542 shares of the company’s stock, valued at approximately $117,667.20. This trade represents a 37.35% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 92,500 shares of company stock valued at $148,000 in the last three months. Company insiders own 18.00% of the company’s stock.

About Biomerica

Biomerica, Inc is a medical diagnostics company that develops and commercializes products designed to help diagnose and manage gastrointestinal and other health conditions. The company focuses on tests and related solutions intended to support more personalized treatment decisions.

Biomerica’s best-known product platform is inFoods, which uses blood-based testing to identify foods that may contribute to symptoms associated with gastrointestinal disorders. The company has emphasized inFoods IBS, a diagnostic-guided dietary management solution for people with irritable bowel syndrome, pairing test results with individualized food recommendations.

Biomerica also has developed and marketed diagnostic products for conditions including Helicobacter pylori infection, allergies and respiratory illnesses.